116 related articles for article (PubMed ID: 20421867)
1. A randomized, double-blind, placebo-controlled trial of valacyclovir prophylaxis to prevent zoster recurrence from months 4 to 24 after BMT.
Klein A; Miller KB; Sprague K; DesJardin JA; Snydman DR
Bone Marrow Transplant; 2011 Feb; 46(2):294-9. PubMed ID: 20421867
[TBL] [Abstract][Full Text] [Related]
2. One-year low-dose valacyclovir as prophylaxis for varicella zoster virus disease after allogeneic hematopoietic stem cell transplantation. A prospective study of the Japan Hematology and Oncology Clinical Study Group.
Oshima K; Takahashi T; Mori T; Matsuyama T; Usuki K; Asano-Mori Y; Nakahara F; Okamoto S; Kurokawa M; Kanda Y
Transpl Infect Dis; 2010 Oct; 12(5):421-7. PubMed ID: 20626711
[TBL] [Abstract][Full Text] [Related]
3. Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.
Lowance D; Neumayer HH; Legendre CM; Squifflet JP; Kovarik J; Brennan PJ; Norman D; Mendez R; Keating MR; Coggon GL; Crisp A; Lee IC
N Engl J Med; 1999 May; 340(19):1462-70. PubMed ID: 10320384
[TBL] [Abstract][Full Text] [Related]
4. An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients.
Fife KH; Warren TJ; Justus SE; Heitman CK;
Sex Transm Dis; 2008 Jul; 35(7):668-73. PubMed ID: 18461016
[TBL] [Abstract][Full Text] [Related]
5. Valacyclovir for prevention of recurrent herpes labialis: 2 double-blind, placebo-controlled studies.
Baker D; Eisen D
Cutis; 2003 Mar; 71(3):239-42. PubMed ID: 12661753
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the efficacy and safety of valaciclovir versus acyclovir in the treatment of herpes zoster.
Lin WR; Lin HH; Lee SS; Tsai HC; Huang CK; Wann SR; Chen YS; Chiang SC; Yen MY; Liu YC
J Microbiol Immunol Infect; 2001 Jun; 34(2):138-42. PubMed ID: 11456360
[TBL] [Abstract][Full Text] [Related]
7. Daily 500 mg valacyclovir is effective for prevention of Varicella zoster virus reactivation in patients with multiple myeloma treated with bortezomib.
Fukushima T; Sato T; Nakamura T; Iwao H; Nakajima A; Miki M; Sakai T; Kawanami T; Sawaki T; Fujita Y; Tanaka M; Masaki Y; Okazaki T; Nakajima H; Motoo Y; Umehara H
Anticancer Res; 2012 Dec; 32(12):5437-40. PubMed ID: 23225448
[TBL] [Abstract][Full Text] [Related]
8. Valacyclovir for the suppression of recurrent genital herpes in human immunodeficiency virus-infected subjects.
DeJesus E; Wald A; Warren T; Schacker TW; Trottier S; Shahmanesh M; Hill JL; Brennan CA;
J Infect Dis; 2003 Oct; 188(7):1009-16. PubMed ID: 14513421
[TBL] [Abstract][Full Text] [Related]
9. Valomaciclovir versus valacyclovir for the treatment of acute herpes zoster in immunocompetent adults: a randomized, double-blind, active-controlled trial.
Tyring SK; Plunkett S; Scribner AR; Broker RE; Herrod JN; Handke LT; Wise JM; Martin PA;
J Med Virol; 2012 Aug; 84(8):1224-32. PubMed ID: 22711350
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of valacyclovir for the suppression and episodic treatment of herpes simplex virus in patients with HIV.
Warren T; Harris J; Brennan CA
Clin Infect Dis; 2004 Nov; 39 Suppl 5():S258-66. PubMed ID: 15494897
[TBL] [Abstract][Full Text] [Related]
11. Long-term ultra-low-dose acyclovir against varicella-zoster virus reactivation after allogeneic hematopoietic stem cell transplantation.
Asano-Mori Y; Kanda Y; Oshima K; Kako S; Shinohara A; Nakasone H; Sato H; Watanabe T; Hosoya N; Izutsu K; Asai T; Hangaishi A; Motokura T; Chiba S; Kurokawa M
Am J Hematol; 2008 Jun; 83(6):472-6. PubMed ID: 18266207
[TBL] [Abstract][Full Text] [Related]
12. Valacyclovir for the prevention of cytomegalovirus infection after allogeneic stem cell transplantation: a single institution retrospective cohort analysis.
Vusirikala M; Wolff SN; Stein RS; Brandt SJ; Morgan DS; Greer JP; Schuening FG; Dummer JS; Goodman SA
Bone Marrow Transplant; 2001 Aug; 28(3):265-70. PubMed ID: 11535994
[TBL] [Abstract][Full Text] [Related]
13. Open-label study of valacyclovir 1.5 g twice daily for the treatment of uncomplicated herpes zoster in immunocompetent patients 18 years of age or older.
Madkan VK; Arora A; Babb-Tarbox M; Aboutlabeti S; Tyring S
J Cutan Med Surg; 2007; 11(3):89-98. PubMed ID: 17511925
[TBL] [Abstract][Full Text] [Related]
14. Clinical utility of oral valacyclovir compared with oral acyclovir for the prevention of herpes simplex virus mucositis following autologous bone marrow transplantation or stem cell rescue therapy.
Eisen D; Essell J; Broun ER; Sigmund D; DeVoe M
Bone Marrow Transplant; 2003 Jan; 31(1):51-5. PubMed ID: 12621507
[TBL] [Abstract][Full Text] [Related]
15. A large-scale, placebo-controlled, dose-ranging trial of peroral valaciclovir for episodic treatment of recurrent herpes genitalis. Valaciclovir HSV Study Group.
Spruance SL; Tyring SK; DeGregorio B; Miller C; Beutner K
Arch Intern Med; 1996 Aug 12-26; 156(15):1729-35. PubMed ID: 8694673
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of valacyclovir vs acyclovir for the prevention of recurrent herpes simplex virus eye disease: a pilot study.
Miserocchi E; Modorati G; Galli L; Rama P
Am J Ophthalmol; 2007 Oct; 144(4):547-51. PubMed ID: 17692271
[TBL] [Abstract][Full Text] [Related]
17. Factors influencing varicella zoster virus infection after allogeneic peripheral blood stem cell transplantation: low-dose acyclovir prophylaxis and pre-transplant diagnosis of lymphoproliferative disorders.
Kim DH; Messner H; Minden M; Gupta V; Kuruvilla J; Wright J; Lipton J
Transpl Infect Dis; 2008 Apr; 10(2):90-8. PubMed ID: 17605742
[TBL] [Abstract][Full Text] [Related]
18. Suppressive therapy with valacyclovir in early genital herpes: a pilot study of clinical efficacy and herpes-related quality of life.
Handsfield HH; Warren T; Werner M; Phillips JA
Sex Transm Dis; 2007 Jun; 34(6):339-43. PubMed ID: 17065847
[TBL] [Abstract][Full Text] [Related]
19. Double-blind study comparing 2 dosages of valacyclovir hydrochloride for the treatment of uncomplicated herpes zoster in immunocompromised patients 18 years of age and older.
Arora A; Mendoza N; Brantley J; Yates B; Dix L; Tyring S
J Infect Dis; 2008 May; 197(9):1289-95. PubMed ID: 18422441
[TBL] [Abstract][Full Text] [Related]
20. Valacyclovir for episodic treatment of genital herpes: a shorter 3-day treatment course compared with 5-day treatment.
Leone PA; Trottier S; Miller JM
Clin Infect Dis; 2002 Apr; 34(7):958-62. PubMed ID: 11880962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]